Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 13,736 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Asthma
Interventions: Fluticasone propionate, Placebo, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: ICD implantation; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 3,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Portland, Maine • Baltimore, Maryland • Boston, Massachusetts + 10 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: cisplatin, paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 52
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 42 more

Conditions: Hand Hygiene
Interventions: Donning Non-Sterile Gloves without HH; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 14,418 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Iowa City, Iowa • Baltimore, Maryland

Conditions: Sepsis
Interventions: Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more

Conditions: Pulmonary Arterial Hypertension
Interventions: imatinib mesylate, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: HIV Infections
Interventions: Chloroquine, Placebo; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more

Conditions: Systemic Lupus Erythematosus
Interventions: Levothyroxine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: galantamine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 60 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: Placebo, mirabegron, moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Primary Immunodeficiency
Interventions: IgPro; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Litchfield Park, Arizona • Scottsdale, Arizona • Centennial, Colorado + 5 more

Conditions: Peritoneal Carcinomatosis
Interventions: Intraperitoneal docetaxel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: CRC (Colorectal Cancer)
Interventions: Ruxolitinib, Regorafenib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 57
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more

Conditions: Comorbidities and Coexisting Conditions, Risk Reduction, Emergencies
Interventions: High Risk Clinic; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
Interventions: Peanut powder, Peanut extract, Placebo extract, Placebo powder; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions: Cisplatin, IMRT 6 weeks, IMRT 5 weeks; Drug · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 207
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 168 more

Conditions: Healthy
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 409
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan, Irinotecan Sucrosofate, Leucovorin, Nab-paclitaxel, Panitumumab, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 274
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more

Conditions: Cachexia
Interventions: GSK2881078, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Baltimore, Maryland

Conditions: Cerebral Palsy (CP)
Interventions: dalfampridine-ER 10mg, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Birmingham, Alabama • Downey, California • Los Angeles, California + 8 more

Conditions: Drug Addiction
Interventions: Enhanced care, control; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Covid19
Interventions: VIR-7831 (sotrovimab), Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 13 Years and older
Enrollment: 2,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2013
U.S. locations: 19
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 14 more

Search by objective public record fields.

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

Direct Gloving Strategy: A Cluster-randomized Trial

Vitamin C, Thiamine, and Steroids in Sepsis

Imatinib (QTI571) in Pulmonary Arterial Hypertension

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

Levothyroxine in Pregnant SLE Patients

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis

Study of Ruxolitinib in Colorectal Cancer Patients

High Risk Outpatient Intern-led Care (HeROIC) Clinic Initiative

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Treating the Partners of Drug Using Pregnant Women: Stage II

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Longitudinal Study of Ocular Complications of AIDS (LSOCA)